Haupt D, Rosenblatt L, Kim E, Baker R, Whitehead R, Newcomer J. Prevalence and Predictors of Lipid and Glucose Monitoring among Commercially Insured Patients Treated with Second-Generation Antipsychotic Agents.American Journal of Psychiatry; in press. 2008.
Tandon R. Safety and tolerability: how do newer generation "atypical" antipsychotics compare? Psychiatr Q.2002;73(4):297–311.
ADA/APA/AACE/NAASO. Consensus development conference on antipsychotic drugs and obesity and diabetes. American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity Diabetes Care. 2004;27(2):596–601.
Lambert BL, Cunningham FE, Miller DR, Dalack GW, Hur K. Diabetes risk associated with use of olanzapine, quetiapine, and risperidone in veterans health administration patients with schizophrenia. Am J Epidemiol.2006;164(7):672–681.
Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs. 2005;19(Suppl 1):1–93.
Ramaswamy K, Masand PS, Nasrallah HA. Do certain atypical antipsychotics increase the risk of diabetes? A critical review of 17 pharmacoepidemiologic studies. Ann Clin Psychiatry. 2006;18(3):183–194.
Citrome L. Olanzapine: interpreting the label change. Int J Clin Pract. 2007;61(12):1960–1962.
Hedenmalm K, Hagg S, Stahl M, Mortimer O, Spigset O. Glucose intolerance with atypical antipsychotics. Drug Saf. 2002;25(15):1107–1116.
Henderson DC, Cagliero E, Copeland PM, Borba CP, Evins E, Hayden D, Weber MT, Anderson EJ, Allison DB, Daley TB, Schoenfeld D, Goff DC. Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis. Arch Gen Psychiatry. 2005;62(1):19–28.
Koller E, Schneider B, Bennett K, Dubitsky G. Clozapine-associated diabetes. Am J Med. 2001;111(9):716–723.
Koller EA, Weber J, Doraiswamy PM, Schneider BS. A survey of reports of quetiapine-associated hyperglycemia and diabetes mellitus. J Clin Psychiatry. 2004;65(6):857–863.
Scheen AJ, De Hert MA. Abnormal glucose metabolism in patients treated with antipsychotics. Diabetes Metab.2007;33:169-175.
Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353(12):1209–1223.
Montes JM, Rodriguez JL, Balbo E, Sopelana P, Martin E, Soto JA, Delgado JF, Diez T, Villardaga I. Improvement in antipsychotic-related metabolic disturbances in patients with schizophrenia switched to ziprasidone. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31(2):383–388.
De Hert M, Hanssens L, van Winkel R, Wampers M, Van Eyck D, Scheen A, Peuskens J. Reversibility of antipsychotic treatment-related diabetes in patients with schizophrenia: a case series of switching to aripiprazole.Diabetes Care. 2006;29(10):2329–2330.
De Hert M, Hanssens L, van Winkel R, Wampers M, Van Eyck D, Scheen A, Peuskens J. A Case Series: Evaluation of the Metabolic Safety of Aripiprazole. Schizophr Bull. 2007;33(33):823–830.
Albaugh VL, Henry CR, Bello NT, Hajnal A, Lynch SL, Halle B, Lynch CJ. Hormonal and metabolic effects of olanzapine and clozapine related to body weight in rodents. Obesity (Silver Spring). 2006;14(1):36-51.
ADA. Position statements and ADA statements. Diabetes Care. 2006;29(Suppl 1):S75–77.
Houseknecht KL, Robertson AS, Zavadoski W, Gibbs EM, Johnson DE , Rollema H. Acute effects of atypical antipsychotics on whole-body insulin resistance in rats: implications for adverse metabolic effects.Neuropsychopharmacology. 2007;32(2):289–297.
Johnson DE, Yamazaki H, Ward KM, Schmidt AW, Lebel WS, Treadway JL, Gibbs EM, Zawalich WS, Rollema H. Inhibitory effects of antipsychotics on carbachol-enhanced insulin secretion from peri-fused rat islets: role of muscarinic antagonism in antipsychotic-induced diabetes and hyperglycemia. Diabetes. 2005;54(5):1552–1558.
Rodriguez EM, Staffa JA, Graham DJ. The role of databases in drug postmarketing surveillance.Pharmacoepidemiol Drug Saf. 2001;10(5):407–410.
DuMouchel W. Bayesian Data Mining in Large Frequency Tables, With an Application to the FDA Spontaneous Reporting System. The American Statistician. 1999;53:177-190.
Hastie T, Tibshirani R, Friedman J.The Elements of Statistical Learning: Data Mining, Inference and Prediction. New York: Springer, 2001.
Hauben M, Horn S, Reich L. Potential use of data-mining algorithms for the detection of 'surprise' adverse drug reactions. Drug Saf. 2007;30(2):143–155.
Szarfman A, Machado SG, O'Neill RT Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA's spontaneous reports database. Drug Saf.2002;25(6):381–392.
DuMouchel W, Fram D, Yang X, Mahmoud RA, Grogg AL, Engelhart L, Ramaswamy K. Antipsychotics, glycemic disorders, and life-threatening diabetic events: a Bayesian data-mining analysis of the FDA adverse event reporting system (1968–2004). Ann Clin Psychiatry. 2008;20(1):21–31.
Buse JB, Cavazzoni P, Hornbuckle K, Hutchins D, Breier A, Jovanovic L. A retrospective cohort study of diabetes mellitus and antipsychotic treatment in the United States./Clin Epidemiol. 2003;56(2):164-170.
McQuade RD, Stock E, Marcus R, Jody D, Gharbia NA, Vanveggel S, Archibald D, Carson WH. A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study./Clin Psychiatry. 2004;65(Suppl 18):47–56.
Simpson GM, Glick ID, Weiden PJ, Romano SJ , Siu CO. Randomized, controlled, double-blind mul-ticenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder. Am J Psychiatry. 2004;161(10):1837–1847.
Fegert JM. [Specific features and problems in the pharmacotherapy of schizophrenic psychoses in children and adolescents]. Z Arztl Fortbild Qualitatssich. 2002;96(9):597–603.
Hugtenburg JG, Heerdink ER, Tso YH. Psychoactive drug prescribing by Dutch child and adolescent psychiatrists. Acta Paediatr. 2005;94(10):1484–1487.
Medco Health Solutions.Growth in medication use in children—2001–2006. Franklin Lakes, NJ: Medco Health Solutions, 2007.
Zito JM, Safer DJ, dosReis S, Gardner JF, Boles M, Lynch FTrends in the prescribing of psychotropic medications to preschoolers. Jama. 2000;283(8):1025–1030.
Joukamaa M, Koskinen S, Lonnqvist J, Reunanen A.
Type 2 diabetes among persons with schizophrenia and
other psychotic disorders in a general population survey
Eur Arch Psychiatry Clin Neurosci. 2007;258(3):129–136.
Increased prevalence of type 2 diabetes mellitus among
psychiatric inpatients with bipolar I affective and
schizoaffective disorders independent of psychotropic drug use.
J Affect Disord. 2002;70(1):19–26.
Wampers M, Scheen A, Peuskens J. Screening for
diabetes and other metabolic abnormalities in patients
with schizophrenia and schizoaffective disorder: evaluation
of incidence and screening methods.
J Clin Psychiatry. 2006;67(10):1493–1500.
Heald A, Hill J, Millar H, Peveler R, Rees A, Singh V,
Taylor D, Vora J, Jones P Minimising metabolic and
cardiovascular risk in schizophrenia: diabetes, obesity
and dyslipidaemia.
J Psychopharmacol OnlineFirst, published on April 19th, 2007;21(4):357–373.
Schizophrenia and increased risks of cardiovascular disease.
Am Heart J. 2005;150(6):1115–1121.
Schizophrenia and comorbid metabolic disorders.
Source
Boston, MA 02114, USA. dhenderson@partners.org
Metabolic syndrome in bipolar disorder: findings from
the Bipolar Disorder Center for Pennsylvanians.
Bipolar Disord. 2005;7(5):424–430.
Sullivan L, Meltzer HY, Hsiao J, Scott Stroup T,
Lieberman JA.
Prevalence of the metabolic syndrome in patients
with schizophrenia: Baseline results from the
Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE)
schizophrenia trial and comparison with national estimates from
NHANES III. Schizophr Res. 2005;80:19-32.